Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded on September 6, 2016 and is headquartered in Saint-Laurent, Canada.
相关临床试验
7
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
3
42.9%
已完成
1
14.3%
终止
3
42.9%
暂无批准数据
- DNA Damage Response inhibitors surpassed $7 billion in global sales in 2025, with the broader oncology market projected to approach $500 billion by 2032. - Onco-Innovations is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor that extended median survival to 60 days versus 23 days in PTEN-deficient colorectal cancer mouse models. - The company holds exclusive global rights across three IP layers—core molecules, nanoparticle delivery, and synthetic lethality applications—with a first-in-human phase 1 trial anticipated for late 2026. - Artios Pharma, MD Anderson, and Repare Therapeutics have all generated clinical signals from novel DDR targets beyond PARP, confirming the sector's investable maturity.
- Repare Therapeutics has entered into a definitive agreement to be acquired by non-profit biotechnology company XenoTherapeutics for an estimated $1.82 per share plus contingent value rights. - Shareholders will receive additional payments through CVRs tied to existing partnerships with Bristol-Myers Squibb, Debiopharm, and DCx Biotherapeutics, with percentages ranging from 75% to 100% over 10 years. - The transaction is expected to close in the first quarter of 2026, subject to shareholder approval and court approval under Quebec's Business Corporations Act. - Repare will become a privately held company following the acquisition, with shares expected to be delisted from Nasdaq and deregistered under U.S. and Canadian securities laws.
- Repare Therapeutics has agreed to be acquired by XenoTherapeutics Inc. for $1.82 per share in cash, with shareholders also receiving contingent value rights for future milestone payments. - The acquisition follows a strategic review by Repare's board and is expected to close in the first quarter of 2026, with approximately 40% of shareholders already committed to supporting the transaction. - Prior to the acquisition, Repare secured significant partnerships including a $10 million upfront payment from Debiopharm for lunresertib licensing and a $4 million deal with DCx Biotherapeutics for its discovery platforms.
- Repare Therapeutics will present initial safety, tolerability and early efficacy data from the Phase 1 LIONS trial of RP-1664 at the 37th AACR-NCI-EORTC International Conference on October 25, 2025. - RP-1664 is a potential first-in-class, highly selective oral PLK4 inhibitor designed to target TRIM37-high solid tumors through synthetic lethality mechanisms. - The LIONS trial is a first-in-human, multicenter Phase 1 study investigating RP-1664 monotherapy in adult and adolescent patients with TRIM37-high solid tumors. - Elevated TRIM37 is found across various solid tumors and in approximately 80% of all high-grade neuroblastomas, representing a significant patient population.
- Nilo Therapeutics launched with $101 million Series A financing led by The Column Group, DCVC Bio, and Lux Capital to develop a new class of medicines targeting neural circuits in immune diseases. - The company is pioneering a differentiated approach to immunomodulation by targeting specific vagal neurons that regulate systemic immune activation and inflammation, moving beyond conventional immunosuppression. - Founded by world-leading scientists from Columbia, Yale, and Harvard universities, Nilo appointed Kim Seth as CEO to lead the transition from stealth mode and advance preclinical programs. - The therapeutic approach aims to modulate multiple immune pathways simultaneously by targeting "master regulator" brain-body circuits, potentially reducing therapeutic resistance across autoimmune and inflammatory diseases.
- Repare Therapeutics narrowed its Q2 2025 GAAP loss per share to $0.39, significantly beating analyst estimates of -$0.56, primarily driven by a $5.7 million gain from technology platform licensing deals. - The precision oncology company reduced operating expenses by 38.3% year-over-year while securing major partnerships, including a $10 million upfront licensing deal with Debiopharm for its PKMYT1 inhibitor lunresertib. - Two key clinical trials, POLAR for RP-3467 targeting DNA polymerase theta and LIONS for RP-1664 targeting PLK4 kinase, are expected to report initial findings by the end of 2025.
- Repare Therapeutics has entered into an exclusive worldwide licensing agreement with Debiopharm for lunresertib, a first-in-class PKMYT1 inhibitor targeting difficult-to-treat solid tumors. - The deal includes $10 million upfront payment and up to $257 million in potential milestones, with Debiopharm taking over development activities and the MYTHIC study. - Lunresertib has shown promising Phase 1/1b clinical data, particularly in combination with Debio 0123, a WEE1 inhibitor, demonstrating potential for rapid tumor regressions. - Repare will focus on advancing its remaining pipeline with Phase 1 trials POLAR (RP-3467 Polθ inhibitor) and LIONS (RP-1664 PLK4 inhibitor), with readouts expected in Q3 and Q4 2025.
- Repare Therapeutics has out-licensed its discovery platforms to newly-launched DCx Biotherapeutics for $4 million upfront plus equity stake and potential milestone payments, allowing Repare to focus on its clinical-stage oncology assets. - The deal includes transfer of Repare's SNIPRx, SNIPRx-surf, and STEP2 platforms, along with approximately 20 preclinical research employees and laboratory facilities in Montreal to DCx Biotherapeutics. - Repare maintains a 9.99% equity position in DCx with board representation rights and is eligible for future milestone payments and royalties while expecting initial data from two ongoing Phase 1 trials in the second half of 2025.
• Repare Therapeutics' phase I trial of lunresertib and camonsertib in gynecological cancers with specific biomarkers showed mixed results, impacting stock prices. • Beigene secured a global licensing agreement with CSPC for SYH-2039, a phase I MAT2A inhibitor targeting solid tumors, for up to $1.5 billion. • A new study identifies inceptor as a novel insulin receptor that degrades insulin, potentially opening new avenues for diabetes therapeutics. • GC Biopharma will acquire Abo Holdings for $96.28 million to enhance its U.S. plasma business and accelerate the entry of Alyglo (IVIG-SN 10%).
• Repare Therapeutics' shares fell 38% following Phase 1 results of lunresertib and camonsertib in endometrial and platinum-resistant ovarian cancers. • The combination therapy showed a 25.9% overall response rate in endometrial cancer and 37.5% in platinum-resistant ovarian cancer patients. • A significant safety concern arose, with 26.9% of patients experiencing Grade 3 adverse events, including anemia, during the trial. • Despite mixed results, Repare plans to initiate a Phase 3 registrational study in endometrial cancer in the second half of 2025.
